This podcast episode features Chris Gibson, CEO of Recursion, who shares insights into the transformative potential of technology and AI in drug discovery. He highlights Recursion's innovative approach to overcoming the staggering 90% failure rate in clinical trials by creating a vast, multi-layered data set that maps biological systems. Through virtuous cycles of empirical experimentation and AI-driven analysis, Recursion is pioneering a Techbio framework that aims to democratize scientific tools and foster collaboration in drug development. The evolution of their computational infrastructure, including the powerful BioHive supercomputers, illustrates their commitment to marrying technological advancements with biological research, underscoring the critical role of culture and teamwork in achieving scientific innovation.
